Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lomustine + mebendazole
- Development stage
- Unknown
- Lead developer
- NextSource Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of lomustine (CCNU), an alkylating agent of the nitrosourea type, and mebendazole, a repurposed antiparasitic drug. Lomustine interferes with DNA and RNA function by damaging the DNA in cancer cells, while mebendazole has demonstrated anticancer activity through tubulin binding, preventing tubulin polymerization. This combination has been investigated primarily for the treatment of recurrent high-grade gliomas, including glioblastoma.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lomustine + mebendazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lomustine + mebendazole.